Innate Immunity Stimulation Effects on Biomarkers, Cognition, and the Vascular Amyloid Proteome in a Squirrel Monkey Model of Sporadic CAA
先天免疫刺激对散发性 CAA 松鼠猴模型中生物标志物、认知和血管淀粉样蛋白组的影响
基本信息
- 批准号:10503406
- 负责人:
- 金额:$ 84.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-15 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdjuvantAgeAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAmyloidAnimalsAutopsyBehavioralBiological AssayBiological MarkersBiological Response ModifiersBloodBlood VesselsBrainBrain PathologyCellsCerebral Amyloid AngiopathyChronicClinicalClinical TrialsCognitionCognitiveComplicationDataDefectDevelopmentDiffusionDiffusion Magnetic Resonance ImagingDisease ProgressionEffectivenessElderlyEnvironmentEnzyme-Linked Immunosorbent AssayEvaluationFDA approvedFailureFamilyFormalinGoalsHepatitis B VaccinesHumanImageImmuneImmunohistochemistryImmunotherapeutic agentImpaired cognitionIncidenceIndividualInflammationInterventionLabelLesionLinkLiquid substanceMacrophage ActivationMagnetic Resonance ImagingMapsMass Spectrum AnalysisMeasuresMethodsMicrogliaModelingMonitorMonkeysNatural ImmunityNerve DegenerationParaffin EmbeddingPathogenesisPathologicPathologyPatientsPeripheralPhenotypePlayPrimatesProcessProteinsProteomeProteomicsRisk FactorsRoleSafetySaimiriSalineSenile PlaquesSeveritiesSporadic Cerebral Amyloid AngiopathyStimulusStructure of choroid plexusSystemTLR9 geneTechniquesTestingTherapeuticTimeTissue EmbeddingToll-like receptorsTransgenic MiceTranslationsVascular DiseasesWhite Matter Hyperintensityage relatedagedamyloid pathologybiomarker signaturebrain tissuecell typeclinical applicationclinically relevantcognitive benefitscognitive taskcognitive testingcohortcoronavirus diseasedesigndiagnostic biomarkerdiagnostic valueimaging biomarkerimmunoregulationimprovedin vivoinnovationinsightlaser capture microdissectionmagnetic resonance imaging biomarkermouse modelneuropathologynew therapeutic targetnonhuman primatepre-clinicalprematureresponsescreeningsocial grouptau Proteinstau-1traffickingtreatment effecttreatment responsevaccine trialwhite matterwhite matter change
项目摘要
PROJECT SUMMARY
Dysregulation of innate immunity is thought to be a significant contributor to Alzheimer’s disease (AD)
pathogenesis. We have focused on harnessing innate immunity via Toll-like receptor 9 (TLR9) to modulate age-
related defects in immune cells to counteract AD pathology. Our findings from multiple AD pathology transgenic
mouse models provide the first in vivo evidence that stimulation of innate immunity with TLR9 agonist CpG ODN
can reduce behavioral deficits and ameliorate all pathological hallmarks of AD. Most current immunotherapeutic
trials for AD have been associated with a major complication referred to as amyloid-related imaging abnormalities
(ARIA), which is linked to the presence and extent of cerebral amyloid angiopathy (CAA). CAA is present in a
majority of individuals with AD, and its severity is an independent risk factor for cognitive decline. Hence, it is
critical to develop a therapy effective against CAA without inducing ARIA complications. Additionally, the
premature translation of promising transgenic mice data directly to patients has been associated with a very high
clinical trial failure rate. Our recent study established that squirrel monkeys (SQMs), an NHP model that develops
extensive age-dependent CAA unlike other primates, represent an opportune environment for demonstrating the
therapeutic benefits of our immunomodulation using CpG ODN 2006. Here we propose the use of class B CpG
1018, which is currently being tested in clinical trials for a variety of indications. The collective studies are
designed to provide a comprehensive portrayal of CpG 1018 efficacy and long-term safety by integrating biofluid
biomarker signatures with imaging markers, cognitive measures, in addition to neuropathology correlates.
Disease progression and safety will also be monitored by a combination of MRI techniques, which will enable
morphometric characterization and screening for ARIA. The utility of a multi-shell diffusion MRI model to follow
CpG 1018’s treatment effects in vivo on brain microstructural integrity, especially WM integrity changes, will be
validated for the first time. An additional strength of this proposal is the use of our powerful proteomic strategy
to unveil the first comprehensive characterization of the CAA and choroid plexus (CP) proteomes in association
with disease progression and CpG 1018 intervention. This localized proteomic approach is a preferred method
as it combines unbiased mass spectrometry examination with laser capture microdissection to precisely excise
defined neuropathological lesions. A further aim of this study is to map involvement of the CP-CSF system in
immune cell trafficking in response to CpG 1018. Delineating the CAA and CP protein signatures will advance
understanding of CpG 1018’s favorable immunomodulatory capabilities, as well as provide insights into CAA
pathogenesis to improve diagnostic capability. Overall, the interventions described here will provide
essential preclinical evidence that will enhance CpG 1018’s potential for clinical application.
项目摘要
先天免疫失调被认为是阿尔茨海默病(AD)的重要原因
发病机制我们专注于通过Toll样受体9(TLR 9)利用先天免疫来调节年龄,
免疫细胞中的相关缺陷以抵消AD病理。我们的发现来自多种AD病理转基因
小鼠模型提供了第一个体内证据,即用TLR 9激动剂CpG ODN刺激先天免疫
可以减少行为缺陷并改善AD的所有病理特征。最新免疫学
AD的临床试验与淀粉样蛋白相关的影像学异常的主要并发症有关
(ARIA),这与脑淀粉样血管病(CAA)的存在和程度有关。CAA存在于
AD是大多数AD患者的常见病,其严重程度是认知功能下降的独立危险因素。因此,它是
关键是要开发一种有效的治疗CAA,而不诱导ARIA并发症。另夕h
过早地将有希望的转基因小鼠数据直接翻译给患者,
临床试验失败率我们最近的研究确定,松鼠猴(SQM),一种NHP模型,
与其他灵长类动物不同,广泛的年龄依赖性CAA代表了一个展示
使用CpG ODN的免疫调节的治疗益处2006。在此,我们建议使用B类CpG
1018,目前正在临床试验中测试各种适应症。集体研究是
旨在通过整合生物流体,全面描述CpG 1018的功效和长期安全性
除了神经病理学相关性之外,生物标志物签名与成像标志物、认知测量。
还将通过MRI技术的组合监测疾病进展和安全性,这将使
ARIA的形态测定表征和筛选。多壳层扩散MRI模型的实用性
CpG 1018在体内对脑微结构完整性,特别是WM完整性变化的治疗作用将被证实。
第一次验证。这个建议的另一个优点是使用了我们强大的蛋白质组学策略
揭示CAA和脉络丛(CP)蛋白质组相关的第一个全面特征
疾病进展和CpG 1018干预。这种定位蛋白质组学方法是一种优选的方法
因为它结合了无偏质谱检测和激光捕获显微切割,
明确的神经病理学病变。本研究的另一个目的是绘制CP-CSF系统参与
免疫细胞运输响应于CpG 1018。描绘CAA和CP蛋白特征将推进
了解CpG 1018有利的免疫调节能力,并提供对CAA的见解
发病机制,以提高诊断能力。总的来说,本文所述的干预措施将提供
重要的临床前证据,将提高CpG 1018的临床应用潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Henrieta Scholtzova其他文献
Henrieta Scholtzova的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Henrieta Scholtzova', 18)}}的其他基金
Characterization of Biomarkers and the Vascular Amyloid Proteome in a Non-human Primate Model of Alzheimer’s Disease
阿尔茨海默病非人灵长类动物模型中生物标志物和血管淀粉样蛋白组的表征
- 批准号:
10558614 - 财政年份:2022
- 资助金额:
$ 84.12万 - 项目类别:
Innate Immunity Stimulation Effects on Biomarkers, Cognition, and the Vascular Amyloid Proteome in a Squirrel Monkey Model of Sporadic CAA
先天免疫刺激对散发性 CAA 松鼠猴模型中生物标志物、认知和血管淀粉样蛋白组的影响
- 批准号:
10665767 - 财政年份:2022
- 资助金额:
$ 84.12万 - 项目类别:
Characterization of Biomarkers and the Vascular Amyloid Proteome in a Non-human Primate Model of Alzheimer’s Disease
阿尔茨海默病非人灵长类动物模型中生物标志物和血管淀粉样蛋白组的表征
- 批准号:
10433252 - 财政年份:2022
- 资助金额:
$ 84.12万 - 项目类别:
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
在散发性脑淀粉样血管病的非人灵长类动物模型中通过 CpG ODN 刺激先天免疫
- 批准号:
10161870 - 财政年份:2017
- 资助金额:
$ 84.12万 - 项目类别:
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
在散发性脑淀粉样血管病的非人灵长类动物模型中通过 CpG ODN 刺激先天免疫
- 批准号:
9367918 - 财政年份:2017
- 资助金额:
$ 84.12万 - 项目类别:
Testing of Innate Immunity Stimulation via TLR9 on CAA using Non-human Primates.
使用非人类灵长类动物测试通过 TLR9 对 CAA 进行先天免疫刺激。
- 批准号:
8531364 - 财政年份:2012
- 资助金额:
$ 84.12万 - 项目类别:
Testing of Innate Immunity Stimulation via TLR9 on CAA using Non-human Primates.
使用非人类灵长类动物测试通过 TLR9 对 CAA 进行先天免疫刺激。
- 批准号:
8359340 - 财政年份:2012
- 资助金额:
$ 84.12万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Continuing Grant
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 84.12万 - 项目类别:
Research Grant